Wave Life Sciences Files 8-K
Ticker: WVE · Form: 8-K · Filed: Sep 24, 2024 · CIK: 1631574
| Field | Detail |
|---|---|
| Company | Wave Life Sciences Ltd. (WVE) |
| Form Type | 8-K |
| Filed Date | Sep 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulatory
TL;DR
Wave Life Sciences filed an 8-K, likely containing routine updates or disclosures.
AI Summary
Wave Life Sciences Ltd. filed an 8-K on September 24, 2024, to report on other events and financial statements. The filing does not contain specific details about new agreements, material events, or financial figures within the provided text.
Why It Matters
This 8-K filing indicates that Wave Life Sciences Ltd. is providing updates or disclosures to the SEC, which could be material to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K without immediate indication of significant positive or negative events.
Key Players & Entities
- Wave Life Sciences Ltd. (company) — Registrant
- September 24, 2024 (date) — Date of earliest event reported
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits' as items being reported, but the specific details are not provided in the excerpt.
What is the exact date of the earliest event reported?
The earliest event reported is dated September 24, 2024.
Where is Wave Life Sciences Ltd. incorporated?
Wave Life Sciences Ltd. is incorporated in Singapore.
What is the Commission File Number for Wave Life Sciences Ltd.?
The Commission File Number is 001-37627.
What is the primary business of Wave Life Sciences Ltd.?
Wave Life Sciences Ltd. is in the Pharmaceutical Preparations industry, SIC code 2834.
Filing Stats: 649 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2024-09-24 07:34:59
Key Financial Figures
- $0 — of each exchange on which registered $0 Par Value Ordinary Shares WVE The N
Filing Documents
- d876211d8k.htm (8-K) — 27KB
- d876211dex991.htm (EX-99.1) — 29KB
- g876211g0924065450139.jpg (GRAPHIC) — 4KB
- 0001193125-24-224116.txt ( ) — 191KB
- wve-20240924.xsd (EX-101.SCH) — 3KB
- wve-20240924_lab.xml (EX-101.LAB) — 18KB
- wve-20240924_pre.xml (EX-101.PRE) — 11KB
- d876211d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 7.01 is furnished and not filed: Exhibit No. Description 99.1 Press Release issued by Wave Life Sciences Ltd. dated September 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WAVE LIFE SCIENCES LTD. By: /s/ Paul B. Bolno, M.D. Paul B. Bolno, M.D. President and Chief Executive Officer Date: September 24, 2024